摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{2-methoxy-6-[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]pyridin-3-yl}-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrofuro[3,2-c]pyridine-3-carboxamide

中文名称
——
中文别名
——
英文名称
N-{2-methoxy-6-[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]pyridin-3-yl}-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrofuro[3,2-c]pyridine-3-carboxamide
英文别名
US9777020, Example 121;N-[2-methoxy-6-[4-(morpholine-4-carbonyl)piperazin-1-yl]pyridin-3-yl]-6,6-dimethyl-4-oxo-5,7-dihydrofuro[3,2-c]pyridine-3-carboxamide
N-{2-methoxy-6-[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]pyridin-3-yl}-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrofuro[3,2-c]pyridine-3-carboxamide化学式
CAS
——
化学式
C25H32N6O6
mdl
——
分子量
512.566
InChiKey
ZXEXNCWNAOVZTG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    37
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    130
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE
    申请人:AbbVie Inc.
    公开号:US20150210720A1
    公开(公告)日:2015-07-30
    Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , Z 1 , Z 2 , and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    式(I)化合物的药物可接受的盐、酯、酰胺或放射性标记形式,其中R1、Z1、Z2和n如说明书中所定义,可用于治疗通过或通过原肌球蛋白受体激酶(Trk)预防或缓解的病症或障碍。制备这些化合物的方法已被公开。还公开了式(I)化合物的药物组合物,以及使用这些化合物和组合物的方法。
  • US9777020B2
    申请人:——
    公开号:US9777020B2
    公开(公告)日:2017-10-03
  • [EN] FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS FURO-3-CARBOXAMIDE ET MÉTHODES D'UTILISATION
    申请人:ABBVIE INC
    公开号:WO2015112754A1
    公开(公告)日:2015-07-30
    Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
查看更多